Abstract: The present disclosure belongs to the field for preparation of chitosan oligosaccharide, and particularly relates to a chitosan oligosaccharide sulfate and a preparation method thereof. The method is as follows: adding an equal volume of 1.0%-2.0% by mass of potassium sulfate solution into 2.0%-4.0% by mass of chitosan oligosaccharide hydrochloride solution and evenly mixing to obtain a mixed solution, allowing a molar ratio of amino to sulfate ions in the mixed solution to be 2:1, then adding absolute ethyl alcohol to obtain a chitosan oligosaccharide sulfate suspension, standing, filtering, collecting precipitates, washing, drying and smashing to finally obtain the chitosan oligosaccharide sulfate.

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, in treatment of sepsis and hypercytokinemia.

Abstract: The present invention relates to a lysis, binding and/or wash reagent for isolating and/or purifying nucleic acids and a method for isolating and/or purifying nucleic acids.

Abstract: Provided herein are compounds, compositions, and methods for rapid isolation of nucleic acids from a sample.

Abstract: Disclosed is a method for preparing cellulose and lignin oil by depolymerizing lignocellulose without exogenous hydrogen, including: performing reaction on the lignocellulose dispersed into an aqueous medium at 120° C. to 180° C. under the action of a catalyst; and separating a reaction product to obtain the cellulose and the lignin oil. The catalyst includes a carrier and an active ingredient loaded on the carrier, where the active ingredient is selected from one of platinum, palladium, ruthenium and nickel; the carrier is selected from one of a metal oxide, a metal composite material, silicon dioxide, nitrogen-doped carbon, molybdenum carbide and molybdenum nitride; and the metal oxide is selected from one of niobium oxide, tantalum oxide, tungsten oxide, zirconium oxide, aluminum oxide, titanium dioxide and molybdenum oxide.

Abstract: The present invention relates to the compound of formula (1a) wherein a-d and p are 1 or 2, R1-R4 are hydrogen atom or the like, and R18 is —CF3 or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: Provided is DHA, or a composition comprising DHA, for use in treatment of a biofilm in a subject and for use in treatment of a disease or infection associated or caused by a biofilm in a subject.

Abstract: 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).

Abstract: This disclosure relates to pentagalloyl glucose compositions and uses in managing microbial infections and compositions related thereto. In certain embodiments, this disclosure relates to compositions of pentagalloyl glucose. In certain embodiments, this disclosure relates to methods of treating or preventing a microbial infection, e.g., an antimicrobial resistant microbial infection, comprising administering to a subject in need thereof an effective amount of pentagalloyl glucose or salt thereof. In certain embodiments, the microbe is bacteria or fungi resistant to one or more antibiotic agents or antifungal agents.

Abstract: Disclosed is an industrial method for simultaneously preparing Stevia rebaudiana chlorogenic acid and stevioside. The industrial method includes carrying out alcohol extraction on Stevia rebaudiana which is used as a raw material, and then adjusting the feed liquid state to allow chlorogenic acid to be in a free molecular state; carrying out extraction separation by a water-insoluble moderate-polarity organic solvent; enriching the Stevia rebaudiana chlorogenic acid in an organic layer; and enriching the stevioside in a water layer.

Abstract: Terpenoid derivatives for use in the medicinal applications and compositions containing these derivatives. This new generation of compounds possesses selective anti-neurodegenerative properties on neuronal cells and tissues and can be particularly used in the treatment and prophylaxis of neurodegenerative disease, particularly in the treatment and prophylaxis of Parkinson's and Huntington's disease.

Abstract: According to one embodiment, a method of synthesizing an organometallic iridium monomer compound includes obtaining a dimeric iridium compound having a halogenated bridge, refluxing a mixture comprising the dimeric iridium compound, a base, an ancillary ligand, and 1,2-dimethoxyethane for forming a precipitate of an organometallic iridium monomer, and filtering the refluxed mixture to collect the organometallic iridium monomer precipitate.

Abstract: Disclosed herein, inter alia, are silicon containing cleavable linkers and compounds for use in nucleic acid sequencing.

Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.

Abstract: 5?-O-Phenylacetyluridine effectively delivers both phenylacetate and uridine to a subject. It can be used to treat hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.

Abstract: A method for preparing a water-soluble rutin powder includes: heating and mixing a plant polysaccharide substance, a filler, and water to obtain a wall material solution; adding an antioxidant and a rutin powder into the wall material solution at a first temperature, followed by emulsification and dispersion, pH adjustment, and high-pressure homogenization to obtain a rutin powder emulsion; and carrying out heating fusion of the rutin powder emulsion to obtain a water-soluble rutin powder. With the preparation method, a water-soluble rutin product is obtained through emulsification, high-pressure homogenization, ultra-high-temperature fusion, drying and other processes by using modified starch and a plant polysaccharide as a wall material and rutin as a core material.

Abstract: The present invention relates to a process for the preparation of crosslinked hyaluronic acid butyrate or crosslinked hyaluronic acid butyrate-formate or an acceptable salt thereof, wherein the process comprises the crosslinking reaction of hyaluronic acid butyrate or hyaluronic acid butyrate-formate or a pharmaceutically acceptable salt thereof in an organic solvent with a carboxyl activating reagent, characterized in that the hyaluronic acid butyrate or hyaluronic acid butyrate-formate or pharmaceutically acceptable salt thereof is a mixture of a high-molecular-weight polysaccharide and a low-molecular-weight polysaccharide.

Abstract: Provided are methods for producing levulinic acid from hemp hurds. In some embodiments, the methods include dissolving hemp hurds in an ionic liquid medium to produce a cellulose-rich product; hydrolyzing cellulose present in the cellulose-rich product to produce a glucose-rich product; dehydrating glucose present in the glucose-rich product, and/or fructose resulting from isomerization of the glucose, to produce 5-hydroxymethyl furfural (HMF); and hydrolyzing the HMF to levulinic acid.

Abstract: The invention is directed to methods and apparatus for parallel enzymatic synthesis of polynucleotides in an array of reaction chambers using a template-free polymerase that has sequence-dependent coupling efficiencies. Whenever sequences causing low efficiency coupling occur at a 3? end of a growing chain of a polynucleotide being synthesized, one or more additional coupling cycles without de-protection steps are inserted into synthesis plans to provide additional time for completing the coupling reaction at that position of the polynucleotide.

Abstract: The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.